About

Copious research efforts have been undertaken in MS research in the last three decades to unravel immune mechanisms in the periphery thought to be responsible for disease onset and effector mechanisms mediating CNS damage.  However, the underlying molecular causes of MS are still not understood and prognostic estimates can hardly be given to patients in the absence of valid surrogate markers.  Traditional therapeutic disease modifying regimens aim at immunomodulation or immunosuppression and were developed in the context of autoimmune research in conjunction with other diseases such as rheumatoid arthritis, Crohn’s disease and diabetes mellitus.  However, response to anti-inflammatory therapeutic interventions differs significantly between MS and other autoimmune disorders.  Moreover, in many MS patients, response to the current interventions has only limited impact on disease progression.  Finally, novel therapies in MS aimed at reducing the CNS-directed immune responses are associated with a severe risk for opportunistic CNS infection.

There is currently an urgent need to go back to basics and apply completely novel ideas and unconventional methods as well as brand new technologies to research in this area.  Now is the time to take up the challenge and, for the first time in Germany, promote interaction between strong research groups at three different sites that all have the ideal prerequisites for illuminating and expanding highly novel and innovative perspectives in MS research.  The goal of this consortium, which consists of scientists from centers in the Rhine-Main area, Münster and Munich, is to unravel the pathology of MS and develop as well as understand novel therapeutic concepts.  The ideal prerequisites for such progress are provided by effectively linking scientists from neighboring disciplines with classical neuroimmunologists, who possess a proven track record in MS research and patient care and arise from an important and internationally visible nucleus in this field.  One key aspect here is the strong bidirectional crosstalk between pure experimental research in animal models and clinical research in human systems and patients, which allows the best transfer of basic knowledge into clinical care – and vice versa.

News

Tue, 10/07/2018
SFB offers workshop on Bioinformatics
Mainz. SFB Associate Muthuraman Muthuraman cordially invites all members to the “Bioinformatics Workshop” on Monday, September 24, 2018. The one-day event combines lectures on topics such as “Machine learning and statistics”, “Bioinformatics analyses of multi parameter flow cytometry data” and “Computational System Genetics” with a hands-on session. The full program is available here....more
Tue, 05/06/2018
21st Meeting on T-Cells, Subsets and Functions
Marburg. SFB-PI Prof. Dr. Tobias Bopp & Prof. Dr. Magdalena Huber are chairing this year’s “21st Meeting on T-Cells, Subsets and Functions“ in Marburg. The two-day conference covers all recent aspects of T cell subsets, including Th1, Zh2, Th17, CD8 NKT and regulatory T cells When?: Thursday, June 21, 12.00 – 8.00 PM and Wednesday, […]...more
Fri, 25/05/2018
SFB/CRC-TR 128 retreat in Munich
Munich. The CRC-TR 128 “Multiple Sclerosis” cordially invites all its members – principal investigators as well as associated scientists and young investigators – to meet for a general scientific update, discussion and exchange at this year’s retreat. In addition to the PI meeting there will be a one-day conference especially for young investigators. When?: Thursday […]...more